Pfizer (NYSE: PFE; LSE: PFZ) has announced a new collaboration with India's Strides Arcolab Ltd (BSE: 532531, NSE: STAR) to commercialize off-patent sterile injectable and oral products in the United States through its Established Products Business Unit with expectations to deliver 40 off-patent products to healthcare providers and patients in the US.
The first of the products commercialized under this collaboration is expected to be launched in 2010.
These finished dosage form products will be licensed and supplied by Strides and Onco Laboratories Limited and Onco Therapies Limited, two joint ventures between Strides and Aspen, South Africa, in which each has a 50% ownership interest.
“This Strides collaboration is new and exciting, and we are encouraged about the potential of this relationship. In addition, this agreement brings the total number of products in-licensed by our Established Products Business Unit to more than 200, resulting in a total business unit portfolio of approximately 600 high-quality, reliable, and cost effective products for patient,” said president and general manager of Pfizer’s Established Products business unit, David Simmons.
The financial terms of the supply agreement were not disclosed.
Pfizer’s Established Products business unit launched its US Injectables team less than 10 months ago and is already marketing products in the US.
Disclosure: I do not hold a position